LILAC-TIMI 76NCT05712200
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 64 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion dates pushed to Dec 30, 2027
- Enrollment increased: 1900 → 2500 participants
- Trial sites expanded: 734 → 789 locations
- Study description expanded, about 117 words
- Minor Trial sites expanded: 721 → 734 locationsv63
- Minor Study sites: 681 to 721v62
- Minor Study sites: 651 to 681v61
- Minor Study sites: 605 to 651
- Primary completion date: Aug 2026 to Aug 31, 2026
- Study completion date: Oct 2026 to Oct 31, 2026
- Collaborators expanded, about 2 words
Show 44 earlier versionsHide 44 earlier versions
- Minor Study sites: 599 to 605v59
- Minor Study sites: 578 to 599v58
- Minor Study sites: 565 to 578v57
- Minor Study sites: 553 to 565v56
- Minor Study sites: 545 to 553v55
- Minor Study sites: 531 to 545v54
- Minor Study sites: 516 to 531v53
- Minor Study sites: 480 to 516v52
- Minor Study sites: 473 to 480v51
- Minor Study sites: 468 to 473v50
- Minor Study sites: 460 to 468v49
- Minor Study sites: 451 to 460v48
- Minor Study sites: 446 to 451v47
- Minor Study sites: 438 to 446v46
- Minor Study sites: 435 to 438v45
- Minor Study sites: 427 to 435v44
- Minor Study sites: 420 to 427v43
- Minor Study sites: 416 to 420v42
- Minor Study sites: 411 to 416v41
- Minor Study sites: 407 to 411v40
- Minor Study sites: 400 to 407v39
- Notable Primary completion date: Jan 2025 to Aug 2026
- Study sites: 394 to 400
- Study completion date: Mar 2025 to Oct 2026
- Minor Study sites: 391 to 394v37
- Notable Eligibility criteria expanded, about 15 words
- Study sites: 389 to 391
- Minor Study sites: 386 to 389v35
- Minor Study sites: 380 to 386v34
- Minor Study sites: 373 to 380v33
- Minor Study sites: 367 to 373v32
- Minor Study sites: 364 to 367v31
- Minor Study sites: 359 to 364v30
- Minor Study sites: 354 to 359v29
- Notable Eligibility criteria expanded, about 93 words
- Study sites: 339 to 354
- Minor Study sites: 332 to 339v27
- Minor Study sites: 320 to 332v26
- Minor Study sites: 309 to 320v25
- Minor Study sites: 300 to 309v24
- Minor Study sites: 284 to 300v23
- Minor Study sites: 275 to 284v22
- Minor Study sites: 257 to 275v21
- Minor Study sites: 240 to 257v20
- Minor Study sites: 217 to 240v19
- Minor Study sites: 163 to 217v18
- Minor Study sites: 122 to 163v17
- Minor Study sites: 108 to 122v15
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.
Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.
Biologicals: Abelacimab
Drugs: Placebo
Sites
789 sites in 35 countries
United States 174, China 45, Brazil 43, India 37, Argentina 35, Poland 34, Japan 33, Bulgaria 31, Italy 29, United Kingdom 29, Canada 24, Romania 23, Spain 23, Mexico 17, South Korea 17, Hungary 16, Turkey (Türkiye) 15, Colombia 14, Greece 14, Israel 13, Malaysia 13, Serbia 12, Germany 11, Latvia 11, South Africa 11, Chile 10, Czechia 10, Philippines 10, Croatia 9, Slovakia 7, Peru 6, Sweden 4, Estonia 3, Finland 3, Puerto Rico 3